Tandem Diabetes Care (STU:TD5A) Dividends Received

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:TD5A Tandem Diabetes Care Inc STU:TD5A
73 GF Score
Price €18.40
GF Value €21.16
Valuation Modestly Undervalued
! 6 Warning Signs
View Full Analysis

What is Tandem Diabetes Care Dividends Received?

Dividends Received only applicable to companies reporting Cash Flow from Operations in direct method.

STU:TD5A
73GF Score
Tandem Diabetes Care Inc STU:TD5A
Dividends Received is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Tandem Diabetes Care (STU:TD5A) Overvalued in 2026?

Based on GuruFocus' analysis, Tandem Diabetes Care stock appears to be undervalued. The current stock price of €18.40 is trading 13% below its estimated GF Value™ of €21.16. GuruFocus considers Tandem Diabetes Care to be Modestly Undervalued.

Key valuation signals for STU:TD5A:

  • Dividends Received:
  • GF Value™: €21.16 vs. price of €18.40 (13% below fair value)
  • GF Score™: 73/100 with 6 warning signs

No single metric tells the full story. See the STU:TD5A stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Tandem Diabetes Care Business Description

Address 12400 High Bluff Drive, San Diego, CA, USA, 92130
Tandem Diabetes designs, manufactures, and markets durable insulin pumps for individuals with diabetes. The firm first entered this market in 2012 and has since introduced multiple generations of pumps leading to its current t:slim X2 device. The firm recently launched its smaller Mobi pump and continues to work on Tobi (a tubeless version of Mobi), and the Sigi tubeless patch pump. Nearly three-quarters of total revenue is derived from the US, with the remainder primarily from other developed nations. The pumps themselves generate just over half of total sales, and another one-third is from disposable infusion sets that need to be changed over every 2 to 3 days.
73GF Score

Get the complete analysis for STU:TD5A

Dividends Received is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€18.40
Price
€21.16
GF Value